Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells

Hoe-Sup Byun, Susan Pyne, Neil Macritchie, Nigel J Pyne, Robert Bittman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases such as cancer and pulmonary arterial hypertension. We have synthesized inhibitors that are selective for the two isoforms of sphingosine kinase (SK1 and SK2) that catalyze the synthesis of S1P. A thiourea adduct of sphinganine (F02) is selective for SK2 whereas the 1-deoxysphinganines 55-21 and 77-7 are selective for SK1. (2S,3R)-1-Deoxysphinganine (55-21) induced the proteasomal degradation of SK1 in human pulmonary arterial smooth muscle cells and inhibited DNA synthesis, while the more potent SK1 inhibitors PF-543 and VPC96091 failed to inhibit DNA synthesis. These findings indicate that moderate potency inhibitors such as 55-21 are likely to have utility in unraveling the functions of SK1 in inflammatory and hyperproliferative disorders.

LanguageEnglish
Pages1394-1399
Number of pages6
JournalMedChemComm
Volume4
Issue number10
Early online date6 Aug 2013
DOIs
Publication statusPublished - 1 Oct 2013

Fingerprint

Sphingosine
Isoenzymes
Smooth Muscle Myocytes
Muscle
Cells
Degradation
Lung
Thiourea
DNA
Pulmonary Hypertension
Protein Isoforms
Neoplasms
sphingosine kinase
sphingosine 1-phosphate
1-deoxysphinganine
PF-543
safingol

Keywords

  • pulmonary arterial hypertension
  • cancer
  • novel sphingosine kinase 1
  • smooth muscle cell

Cite this

@article{39e6520989a54296ae91251f68d48225,
title = "Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells",
abstract = "Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases such as cancer and pulmonary arterial hypertension. We have synthesized inhibitors that are selective for the two isoforms of sphingosine kinase (SK1 and SK2) that catalyze the synthesis of S1P. A thiourea adduct of sphinganine (F02) is selective for SK2 whereas the 1-deoxysphinganines 55-21 and 77-7 are selective for SK1. (2S,3R)-1-Deoxysphinganine (55-21) induced the proteasomal degradation of SK1 in human pulmonary arterial smooth muscle cells and inhibited DNA synthesis, while the more potent SK1 inhibitors PF-543 and VPC96091 failed to inhibit DNA synthesis. These findings indicate that moderate potency inhibitors such as 55-21 are likely to have utility in unraveling the functions of SK1 in inflammatory and hyperproliferative disorders.",
keywords = "pulmonary arterial hypertension, cancer, novel sphingosine kinase 1, smooth muscle cell",
author = "Hoe-Sup Byun and Susan Pyne and Neil Macritchie and Pyne, {Nigel J} and Robert Bittman",
year = "2013",
month = "10",
day = "1",
doi = "10.1039/C3MD00201B",
language = "English",
volume = "4",
pages = "1394--1399",
journal = "MedChemComm",
issn = "2040-2503",
number = "10",

}

TY - JOUR

T1 - Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells

AU - Byun, Hoe-Sup

AU - Pyne, Susan

AU - Macritchie, Neil

AU - Pyne, Nigel J

AU - Bittman, Robert

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases such as cancer and pulmonary arterial hypertension. We have synthesized inhibitors that are selective for the two isoforms of sphingosine kinase (SK1 and SK2) that catalyze the synthesis of S1P. A thiourea adduct of sphinganine (F02) is selective for SK2 whereas the 1-deoxysphinganines 55-21 and 77-7 are selective for SK1. (2S,3R)-1-Deoxysphinganine (55-21) induced the proteasomal degradation of SK1 in human pulmonary arterial smooth muscle cells and inhibited DNA synthesis, while the more potent SK1 inhibitors PF-543 and VPC96091 failed to inhibit DNA synthesis. These findings indicate that moderate potency inhibitors such as 55-21 are likely to have utility in unraveling the functions of SK1 in inflammatory and hyperproliferative disorders.

AB - Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases such as cancer and pulmonary arterial hypertension. We have synthesized inhibitors that are selective for the two isoforms of sphingosine kinase (SK1 and SK2) that catalyze the synthesis of S1P. A thiourea adduct of sphinganine (F02) is selective for SK2 whereas the 1-deoxysphinganines 55-21 and 77-7 are selective for SK1. (2S,3R)-1-Deoxysphinganine (55-21) induced the proteasomal degradation of SK1 in human pulmonary arterial smooth muscle cells and inhibited DNA synthesis, while the more potent SK1 inhibitors PF-543 and VPC96091 failed to inhibit DNA synthesis. These findings indicate that moderate potency inhibitors such as 55-21 are likely to have utility in unraveling the functions of SK1 in inflammatory and hyperproliferative disorders.

KW - pulmonary arterial hypertension

KW - cancer

KW - novel sphingosine kinase 1

KW - smooth muscle cell

U2 - 10.1039/C3MD00201B

DO - 10.1039/C3MD00201B

M3 - Article

VL - 4

SP - 1394

EP - 1399

JO - MedChemComm

T2 - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 10

ER -